Prognostic significance of catalase expression and its regulatory effects on hepatitis B virus X protein (HBx) in HBV-related advanced hepatocellular carcinomas

Oncotarget

Volumn 5, Issue 23, 2014, Pages 12233-12246

  Cho, Mi Young ^a   Cheong, Jae Youn ^b   Lim, Wonchung ^a,d   Jo, Sujin ^a   Lee, Youngsoo ^a   Wang, Hee Jung ^b   Han, Kyou Hoon ^c   Cho, Hyeseong ^a  

^a Ajou University School of Medicine   (South Korea)

^b Ajou University Medical CentSuwon   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d Chongju University   (South Korea)

Author keywords

Catalase; Cysteine; HBx; Liver cancer; ROS

Indexed keywords

CATALASE; HEPATITIS B VIRUS X PROTEIN; REACTIVE OXYGEN METABOLITE; CYSTEINE; TRANSACTIVATOR PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; TRANSACTIVATION ASSAY; CHEMISTRY; COMPLICATION; ENZYMOLOGY; HEPATITIS B; LIVER TUMOR; METABOLISM; OXIDATIVE STRESS; PHYSIOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CATALASE; CELL PROLIFERATION; CYSTEINE; FEMALE; HEPATITIS B; HUMANS; LIVER NEOPLASMS; MALE; OXIDATIVE STRESS; PROGNOSIS; PROTEIN STABILITY; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS;

EID: 84920031402     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2625     Document Type: Article

References (31)

1. Thun MJ, DeLancey JO, Center MM, Jemal A, and Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010; 31:100-110.
2. Parkin DM, Bray FI, and Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001; 37 Suppl 8:S4-66.
3. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM and Thorgeirsson SS. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology. 2006; 130:1117-1128.
4. Matter MS, Decaens T, Andersen JB and Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends. J Hepatol. 2014; 60(4):855-65.
5. Lim W, Kwon SH, Cho H, Kim S, Lee S, Ryu WS and Cho H. HBx targeting to mitochondria and ROS generation are necessary but insufficient for HBV-induced cyclooxygenase-2 expression. J Mol Med (Berl). 2010; 88:359-369.
6. Lara-Pezzi E, Majano PL, Gomez-Gonzalo M, Garcia-Monzon C, Moreno-Otero R, Levrero M and Lopez-Cabrera M. The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes. Hepatology. 1998; 28:1013-1021.
7. Na TY, Shin YK, Roh KJ, Kang SA, Hong I, Oh SJ, Seong JK, Park CK, Choi YL and Lee MO. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 2009; 49:1122-1131.
8. Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, Kim HH, Yang US, Yu DY and Cheong J. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology. 2007; 132:1955-1967.
9. Bergametti F, Sitterlin D and Transy C. Turnover of hepatitis B virus X protein is regulated by damaged DNAbinding complex. J Virol. 2002; 76:6495-6501.
10. Pang R, Lee TK, Poon RT, Fan ST, Wong KB, Kwong YL and Tse E. Pin1 interacts with a specific serineproline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis. Gastroenterology. 2007; 132:1088-1103.
11. Zhao J, Wang C, Wang J, Yang X, Diao N, Li Q, Wang W, Xian L, Fang Z and Yu L. E3 ubiquitin ligase Siah-1 facilitates poly-ubiquitylation and proteasomal degradation of the hepatitis B viral X protein. FEBS Lett. 2011; 585:2943-2950.
12. Wang JH, Yun C, Kim S, Lee JH, Yoon G, Lee MO and Cho H. Reactive oxygen species modulates the intracellular level of HBx viral oncoprotein. Biochem Biophys Res Commun. 2003; 310:32-39.
13. Jin YM, Yun C, Park C, Wang HJ and Cho H. Expression of hepatitis B virus X protein is closely correlated with the high periportal inflammatory activity of liver diseases. J Viral Hepat. 2001; 8:322-330.
14. Lee YI, Hwang JM, Im JH, Kim NS, Kim DG, Yu DY, Moon HB and Park SK. Human hepatitis B virus-X protein alters mitochondrial function and physiology in human liver cells. J Biol Chem. 2004; 279:15460-15471.
15. Connor KM, Hempel N, Nelson KK, Dabiri G, Gamarra A, Belarmino J, Van De Water L, Mian BM and Melendez JA. Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res. 2007; 67:10260-10267.
16. Yun C, Lee JH, Wang JH, Seong JK, Oh SH, Yu DY and Cho H. Expression of hepatitis B virus X (HBx) gene is up-regulated by adriamycin at the post-transcriptional level. Biochem Biophys Res Commun. 2002; 296:1157-1163.
17. Yun C, Lee JH, Park H, Jin YM, Park S, Park K and Cho H. Chemotherapeutic drug, adriamycin, restores the function of p53 protein in hepatitis B virus X (HBx) protein-expressing liver cells. Oncogene. 2000; 19:5163-5172.
18. Sirma H, Weil R, Rosmorduc O, Urban S, Israel A, Kremsdorf D and Brechot C. Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome. Oncogene. 1998; 16:2051-2063.
19. Rahmani Z, Huh KW, Lasher R and Siddiqui A. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential. J Virol. 2000; 74:2840-2846.
20. Kaveri Sidhu, Saravanan Kumar, Vanga Siva Reddy and Vijay Kumar. Mass spectrometric determination of disulfide bonds in the biologically active recombinant HBx protein of Hepatitis B virus. Biochemistry. 2014; 53:4685-4695.
21. Gupta A, Mal TK, Jayasuryan N and Chauhan VS. Assignment of disulphide bonds in the X protein (HBx) of hepatitis B virus. Biochem Biophys Res Commun. 1995; 212:919-924.
22. Ti Li, Eva I Robert, Pieter C van Breugel, Michel Strubin and Ning Zheng. A promiscuous α-helical motif anchors viral hijackers and substrate receptors to the CUL4-DDB1 ubiquitin ligase machinery. Nat Struct Mol Biol. 2010; 17(1):105-112.
23. Hideki Kusunoki, Toshiyuki Tanaka, Toshiyuki Kohno, Kaori Wakamatsu, Isao Hamaguchi. Structural characterization of the BH3-like motif of hepatitis B virus X protein. Biochem Biophys Res Commun. 2014; 450:741-745.
24. Nair J, Srivatanakul P, Haas C, Jedpiyawongse A, Khuhaprema T, Seitz HK and Bartsch H. High urinary excretion of lipid peroxidation-derived DNA damage in patients with cancer-prone liver diseases. Mutat Res. 2010; 683:23-28.
25. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378-390.
26. Zhang T, Zhang J, You X, Liu Q, Du Y, Gao Y, Shan C, Kong G, Wang Y, Yang X, Ye L and Zhang X. Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology. 2012; 56:2051-2059.
27. Yen CJ, Lin YJ, Yen CS, Tsai HW, Tsai TF, Chang KY, Huang WC, Lin PW, Chiang CW and Chang TT. Hepatitis B virus X protein upregulates mTOR signaling through IKKbeta to increase cell proliferation and VEGF production in hepatocellular carcinoma. PLoS One. 2012; 7:e41931.
28. You X, Liu F, Zhang T, Lv N, Liu Q, Shan C, Du Y, Kong G, Wang T, Ye L and Zhang X. Hepatitis B virus X protein upregulates Lin28A/Lin28B through Sp-1/c-Myc to enhance the proliferation of hepatoma cells. Oncogene. 2014;.33:449-460.
29. Ranasinghe S and McManus DP. Structure and function of invertebrate Kunitz serine protease inhibitors. Dev Comp Immuno.l 2013; 39:219-227.
30. Nishikawa M, Tamada A, Hyoudou K, Umeyama Y, Takahashi Y, Kobayashi Y, Kumai H, Ishida E, Staud F, Yabe Y, Takakura Y, Yamashita F and Hashida M. Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice. Clin Exp Metastasis. 2004; 21:213-221.
31. Gupta A, Butts B, Kwei KA, Dvorakova K, Stratton SP, Briehl MM and Bowden GT. Attenuation of catalase activity in the malignant phenotype plays a functional role in an in vitro model for tumor progression. Cancer Lett. 2001; 173:115-125.